As a key mediator in immune responses and inflammatory pathways, CXCL10 has been identified as an effective prognostic marker significantly associated with the success of DAA treatment and SVR.[35] The regulation of CXCL10, resulting from DAA treatment, may improve glycemic control through its effects on liver function and metabolic homeostasis.[36] Inhibition of inflammatory factors, including CXCL10 by DAAs, may influence the development of diabetes by reducing insulin resistance and metabolic disorders. This evidence concerns the gene CXCL10 and Other metabolic disease.